{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:38:42Z","timestamp":1784115522560,"version":"3.55.0"},"reference-count":86,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Melanoma is one of the most aggressive skin cancers. The 5-year survival rate of stage III melanoma patients ranges from 93% (IIIA) to 32% (IIID) with a high risk of recurrence after complete surgery. The introduction of target and immune therapies has dramatically improved the overall survival, but the identification of patients with a high risk of relapse who will benefit from adjuvant therapy and the determination of the best treatment choice remain crucial. Currently, patient prognosis is based on clinico-pathological features, highlighting the urgent need of predictive and prognostic markers to improve patient management. In recent years, many groups have focused their attention on identifying molecular biomarkers with prognostic and predictive potential. In this review, we examined the main candidate biomarkers reported in the literature.<\/jats:p>","DOI":"10.3390\/ijms22094561","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T06:19:11Z","timestamp":1619504351000},"page":"4561","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6790-554X","authenticated-orcid":false,"given":"Luca","family":"Tonella","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Pala","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Ponti","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1706-656X","authenticated-orcid":false,"given":"Marco","family":"Rubatto","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8390-4467","authenticated-orcid":false,"given":"Giuseppe","family":"Gallo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-3219","authenticated-orcid":false,"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Avallone","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Merli","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Agostini","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-7458","authenticated-orcid":false,"given":"Paolo","family":"Fava","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9887-7668","authenticated-orcid":false,"given":"Luca","family":"Bertero","sequence":"additional","affiliation":[{"name":"Department of Oncology, Pathology Unit, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Senetta","sequence":"additional","affiliation":[{"name":"Department of Oncology, Pathology Unit, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9886-7694","authenticated-orcid":false,"given":"Simona","family":"Osella-Abate","sequence":"additional","affiliation":[{"name":"Department of Oncology, Pathology Unit, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Fierro","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000445767","article-title":"What Is New in Melanoma Genetics and Treatment?","volume":"232","author":"Ribero","year":"2016","journal-title":"Dermatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2004.10.015","article-title":"Meta-Analysis of Risk Factors for Cutaneous Melanoma: I. Common and Atypical Naevi","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2004.10.016","article-title":"Meta-Analysis of Risk Factors for Cutaneous Melanoma: II. Sun Exposure","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/bjd.13500","article-title":"Socioeconomic and Lifestyle Factors and Melanoma: A Systematic Review","volume":"172","author":"Jiang","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejca.2020.11.036","article-title":"Differences in Cutaneous Melanoma Survival between the 7th and 8th Edition of the American Joint Committee on Cancer (AJCC). A Multicentric Population-Based Study","volume":"145","author":"Podlipnik","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual: Melanoma Staging: AJCC 8th Edition","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2015.11.014","article-title":"Long Term Follow up of the EORTC 18952 Trial of Adjuvant Therapy in Resected Stage IIB\u2013III Cutaneous Melanoma Patients Comparing Intermediate Doses of Interferon-Alpha-2b (IFN) with Observation: Ulceration of Primary Is Key Determinant for IFN-Sensitivity","volume":"55","author":"Eggermont","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/14712598.2017.1289169","article-title":"Role of Interferon in Melanoma: Old Hopes and New Perspectives","volume":"17","author":"Sanlorenzo","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage IIIB\u2013C and Stage IV Melanoma (CheckMate 238): 4-Year Results from a Multicentre, Double-Blind, Randomised, Controlled, Phase 3 Trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1470-2045(20)30062-0","article-title":"Adjuvant Dabrafenib plus Trametinib versus Placebo in Patients with Resected, BRAFV600-Mutant, Stage III Melanoma (COMBI-AD): Exploratory Biomarker Analyses from a Randomised, Phase 3 Trial","volume":"21","author":"Dummer","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ejca.2008.03.006","article-title":"Prognostic versus Predictive Value of Biomarkers in Oncology","volume":"44","author":"Oldenhuis","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2013.50.7681","article-title":"Nonsentinel Lymph Node Status in Patients with Cutaneous Melanoma: Results from a Multi-Institution Prognostic Study","volume":"32","author":"Pasquali","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The Eighth Edition American Joint Committee on Cancer (AJCC) Melanoma Staging System: Implications for Melanoma Treatment and Care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00403-020-02089-8","article-title":"Tumour-Infiltrating Lymphocyte and Histological Regression in Primary Melanoma","volume":"313","author":"Ribero","year":"2021","journal-title":"Arch. Dermatol. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjd.15552","article-title":"Prognostic Role of Histological Regression in Primary Cutaneous Melanoma: A Systematic Review and Meta-Analysis","volume":"178","author":"Gualano","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_21","first-page":"487","article-title":"Phenotypic Characterisation of Immune Cells Associated with Histological Regression in Cutaneous Melanoma","volume":"51","author":"Conti","year":"2019","journal-title":"Pathology"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Osella-Abate, S., Vignale, C., Annaratone, L., Nocifora, A., Bertero, L., Castellano, I., Avallone, G., Conti, L., Quaglino, P., and Picciotto, F. (2021). Microenvironment in Cutaneous Melanomas: A Gene Expression Profile Study May Explain the Role of Histological Regression. J. Eur. Acad. Dermatol. Venereol., 35.","DOI":"10.1111\/jdv.16784"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/jid.2012.283","article-title":"BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma","volume":"133","author":"Mann","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1158\/1078-0432.CCR-07-4170","article-title":"Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma","volume":"14","author":"John","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"20429","DOI":"10.1073\/pnas.0905139106","article-title":"Immune Profile and Mitotic Index of Metastatic Melanoma Lesions Enhance Clinical Staging in Predicting Patient Survival","volume":"106","author":"Bogunovic","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zager, J.S., Gastman, B.R., Leachman, S., Gonzalez, R.C., Fleming, M.D., Ferris, L.K., Ho, J., Miller, A.R., Cook, R.W., and Covington, K.R. (2018). Performance of a Prognostic 31-Gene Expression Profile in an Independent Cohort of 523 Cutaneous Melanoma Patients. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4016-3"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/bjc.2011.451","article-title":"TYRP1 MRNA Expression in Melanoma Metastases Correlates with Clinical Outcome","volume":"105","author":"Journe","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/bjc.2013.115","article-title":"Tyrosinase-Related Protein 1 MRNA Expression in Lymph Node Metastases Predicts Overall Survival in High-Risk Melanoma Patients","volume":"108","author":"Journe","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1158\/1078-0432.CCR-09-2721","article-title":"Melanoma MicroRNA Signature Predicts Post-Recurrence Survival","volume":"16","author":"Segura","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Sendra, B., Garc\u00eda-Gim\u00e9nez, J.L., Gonz\u00e1lez-Mu\u00f1oz, J.F., Navarro, L., Murgui, A., Terr\u00e1dez, L., Pinazo, I., Martin, J.M., and Monteagudo, C. (2020). Circulating Mi RNA Expression Analysis Reveals New Potential Biomarkers for Human Cutaneous Melanoma Staging. J. Eur. Acad. Dermatol. Venereol., 34.","DOI":"10.1111\/jdv.16060"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1172\/JCI98060","article-title":"Tumor-Derived MicroRNAs Induce Myeloid Suppressor Cells and Predict Immunotherapy Resistance in Melanoma","volume":"128","author":"Huber","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"E5005","DOI":"10.1073\/pnas.1607753113","article-title":"MiR-579-3p Controls Melanoma Progression and Resistance to Target Therapy","volume":"113","author":"Fattore","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Marczynski, G.T., Laus, A.C., dos Reis, M.B., Reis, R.M., and De Vazquez, V.L. (2020). Circulating Tumor DNA (CtDNA) Detection Is Associated with Shorter Progression-Free Survival in Advanced Melanoma Patients. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-75792-1"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/annonc\/mdz075","article-title":"Pre-Operative CtDNA Predicts Survival in High-Risk Stage III Cutaneous Melanoma Patients","volume":"30","author":"Lee","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/annonc\/mdz048","article-title":"Prediction and Monitoring of Relapse in Stage III Melanoma Using Circulating Tumor DNA","volume":"30","author":"Tan","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/annonc\/mdx717","article-title":"Circulating Tumor DNA Predicts Survival in Patients with Resected High-Risk Stage II\/III Melanoma","volume":"29","author":"Lee","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Gandini, S., Zanna, I., De Angelis, S.P., Cocorocchio, E., Queirolo, P., Lee, J.H., Carlino, M.S., Mazzarella, L., Achutti Duso, B., and Palli, D. (2021). Circulating Tumour DNA and Melanoma Survival: A Systematic Literature Review and Meta-Analysis. Crit. Rev. Oncol. Hematol., 157.","DOI":"10.1016\/j.critrevonc.2020.103187"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1200\/JCO.2005.02.0958","article-title":"Serial Monitoring of Circulating Melanoma Cells During Neoadjuvant Biochemotherapy for Stage III Melanoma: Outcome Prediction in a Multicenter Trial","volume":"23","author":"Koyanagi","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2011.40.0887","article-title":"Association Between Circulating Tumor Cells and Prognosis in Patients With Stage III Melanoma With Sentinel Lymph Node Metastasis in a Phase III International Multicenter Trial","volume":"30","author":"Hoshimoto","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-19-2670","article-title":"Circulating Tumor Cells and Early Relapse in Node-Positive Melanoma","volume":"26","author":"Lucci","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1373\/clinchem.2019.307140","article-title":"Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy","volume":"66","author":"Lin","year":"2020","journal-title":"Clin. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Sigalotti, L., Fratta, E., Bidoli, E., Covre, A., Parisi, G., Colizzi, F., Coral, S., Massarut, S., Kirkwood, J.M., and Maio, M. (2011). Methylation Levels of the \u201cLong Interspersed Nucleotide Element-1\u201d Repetitive Sequences Predict Survival of Melanoma Patients. J. Transl. Med., 9.","DOI":"10.1186\/1479-5876-9-78"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sigalotti, L., Covre, A., Fratta, E., Parisi, G., Sonego, P., Colizzi, F., Coral, S., Massarut, S., Kirkwood, J.M., and Maio, M. (2012). Whole Genome Methylation Profiles as Independent Markers of Survival in Stage IIIC Melanoma Patients. J. Transl. Med., 10.","DOI":"10.1186\/1479-5876-10-185"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/jid.2012.36","article-title":"AIM1 and LINE-1 Epigenetic Aberrations in Tumor and Serum Relate to Melanoma Progression and Disease Outcome","volume":"132","author":"Hoshimoto","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1158\/1078-0432.CCR-08-1361","article-title":"CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma","volume":"15","author":"Tanemura","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/CMR.0000000000000367","article-title":"MGMT Methylation Correlates with Melphalan Pelvic Perfusion Survival in Stage III Melanoma Patients: A Pilot Study","volume":"27","author":"Guadagni","year":"2017","journal-title":"Melanoma Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1016\/j.ejca.2014.06.009","article-title":"BRAF Mutation Status Is an Independent Prognostic Factor for Resected Stage IIIB and IIIC Melanoma: Implications for Melanoma Staging and Adjuvant Therapy","volume":"50","author":"Barbour","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/bjd.12939","article-title":"Is BRAF a Prognostic Factor in Stage III Skin Melanoma? A Retrospective Study of 72 Patients after Positive Sentinel Lymph Node Dissection","volume":"171","author":"Picard","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1245\/s10434-012-2457-5","article-title":"Prognostic Value of BRAF V600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes","volume":"19","author":"Moreau","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG\/KEYNOTE-054 Trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Tas, F., and Erturk, K. (2020). BRAF V600E Mutation as a Prognostic Factor in Cutaneous Melanoma Patients. Dermatol. Ther., 33.","DOI":"10.1111\/dth.13270"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Heppt, M.V., Siepmann, T., Engel, J., Schubert-Fritschle, G., Eckel, R., Mirlach, L., Kirchner, T., Jung, A., Gesierich, A., and Ruzicka, T. (2017). Prognostic Significance of BRAF and NRAS Mutations in Melanoma: A German Study from Routine Care. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3529-5"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/pcmr.12290","article-title":"Protein Signatures Correspond to Survival Outcomes of AJCC Stage III Melanoma Patients","volume":"27","author":"Mactier","year":"2014","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_54","first-page":"1296","article-title":"Serum S100B Levels Correlate with Stage, N Status, Mitotic Rate and Disease Outcome in Melanoma Patients Independent to LDH. 7","volume":"22","author":"Karonidis","year":"2017","journal-title":"J. BUON"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Wagner, N.B., Weide, B., Gries, M., Reith, M., Tarnanidis, K., Schuermans, V., Kemper, C., Kehrel, C., Funder, A., and Lichtenberger, R. (2019). Tumor Microenvironment-Derived S100A8\/A9 Is a Novel Prognostic Biomarker for Advanced Melanoma Patients and during Immunotherapy with Anti-PD-1 Antibodies. J. Immunother. Cancer, 7.","DOI":"10.1186\/s40425-019-0828-1"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1158\/1078-0432.CCR-15-1714","article-title":"PD-L1 Negative Status Is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma","volume":"22","author":"Madore","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1158\/1078-0432.CCR-15-2226","article-title":"Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma","volume":"22","author":"Ekmekcioglu","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.annonc.2019.10.002","article-title":"Prognostic Impact of Baseline Tumour Immune Infiltrate on Disease-Free Survival in Patients with Completely Resected, BRAFv600 Mutation\u2013Positive Melanoma Receiving Adjuvant Vemurafenib","volume":"31","author":"Ascierto","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Lauwyck, J., Beckw\u00e9e, A., Santens, A., Schwarze, J.K., Awada, G., Vandersleyen, V., Aspeslagh, S., and Neyns, B. (2020). 1131P C-Reactive Protein as Biomarker for Immune-Related Adverse Events in Melanoma Patients Treated with Immune Checkpoint Inhibitors in the Adjuvant Setting. Ann. Oncol., 31.","DOI":"10.1016\/j.annonc.2020.08.1254"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.7150\/jca.24744","article-title":"Gene Expression Detection Assay for Cancer Clinical Use","volume":"9","author":"Narrandes","year":"2018","journal-title":"J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jaad.2015.01.009","article-title":"Gene Expression Profiling for Molecular Staging of Cutaneous Melanoma in Patients Undergoing Sentinel Lymph Node Biopsy","volume":"72","author":"Gerami","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/ncb3623","article-title":"A Non-Coding Function of TYRP1 MRNA Promotes Melanoma Growth","volume":"19","author":"Gilot","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.yexcr.2004.04.045","article-title":"Tyrosinase-Related Proteins Suppress Tyrosinase-Mediated Cell Death of Melanocytes and Melanoma Cells","volume":"298","author":"Rad","year":"2004","journal-title":"Exp. Cell Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"31801","DOI":"10.1074\/jbc.273.48.31801","article-title":"Tyrosinase Stabilization by Tyrp1 (the Brown Locus Protein)","volume":"273","author":"Kobayashi","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","article-title":"Survival and Biomarker Analyses from the OpACIN-Neo and OpACIN Neoadjuvant Immunotherapy Trials in Stage III Melanoma","volume":"27","author":"Rozeman","year":"2021","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1016\/j.jid.2020.03.949","article-title":"Defining the Prognostic Role of MicroRNAs in Cutaneous Melanoma","volume":"140","author":"Dika","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.suronc.2016.05.017","article-title":"MicroRNA Dysregulation in Melanoma","volume":"25","author":"Latchana","year":"2016","journal-title":"Surg. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Boyer, M., Cayrefourcq, L., Dereure, O., Meunier, L., Becquart, O., and Alix-Panabi\u00e8res, C. (2020). Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12040960"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41416-020-0750-9","article-title":"Detection and Prognostic Role of Heterogeneous Populations of Melanoma Circulating Tumour Cells","volume":"122","author":"Morici","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2018.03.013","article-title":"Melanoma Circulating Tumor Cells: Benefits and Challenges Required for Clinical Application","volume":"424","author":"Marsavela","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Micevic, G., Theodosakis, N., and Bosenberg, M. (2017). Aberrant DNA Methylation in Melanoma: Biomarker and Therapeutic Opportunities. Clin. Epigenetics, 9.","DOI":"10.1186\/s13148-017-0332-8"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Ascierto, P.A., Kirkwood, J.M., Grob, J.-J., Simeone, E., Grimaldi, A.M., Maio, M., Palmieri, G., Testori, A., Marincola, F.M., and Mozzillo, N. (2012). The Role of BRAF V600 Mutation in Melanoma. J. Transl. Med., 10.","DOI":"10.1186\/1479-5876-10-85"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1038\/onc.2011.160","article-title":"Raf Kinases in Cancer\u2013Roles and Therapeutic Opportunities","volume":"30","author":"Maurer","year":"2011","journal-title":"Oncogene"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Zocco, D., Bernardi, S., Novelli, M., Astrua, C., Fava, P., Zarovni, N., Carpi, F.M., Bianciardi, L., Malavenda, O., and Quaglino, P. (2020). Isolation of Extracellular Vesicles Improves the Detection of Mutant DNA from Plasma of Metastatic Melanoma Patients. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-72834-6"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1084\/jem.20181522","article-title":"Use of Extracellular Vesicles from Lymphatic Drainage as Surrogate Markers of Melanoma Progression and BRAFV600E Mutation","volume":"216","author":"Mazariegos","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","article-title":"Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth","volume":"162","author":"Kleffel","year":"2015","journal-title":"Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/CJI.0000000000000277","article-title":"A Brief Communication on Circulating PD-1-Positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy with Nivolumab","volume":"42","author":"Gambichler","year":"2019","journal-title":"J. Immunother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.molonc.2016.01.009","article-title":"Liquid Biopsy: Potential and Challenges","volume":"10","author":"Pantel","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Yancovitz, M., Litterman, A., Yoon, J., Ng, E., Shapiro, R.L., Berman, R.S., Pavlick, A.C., Darvishian, F., Christos, P., and Mazumdar, M. (2012). Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0029336"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid Biopsies: Genotyping Circulating Tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/14737159.2018.1400384","article-title":"Droplet-Based Digital PCR and next Generation Sequencing for Monitoring Circulating Tumor DNA: A Cancer Diagnostic Perspective","volume":"18","author":"Postel","year":"2018","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Valenti, F., Falcone, I., Ungania, S., Desiderio, F., Giacomini, P., Bazzichetto, C., Conciatori, F., Gallo, E., Cognetti, F., and Ciliberto, G. (2021). Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083837"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1158\/1078-0432.CCR-20-0020","article-title":"Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition","volume":"26","author":"Basler","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Shofty, B., Artzi, M., Shtrozberg, S., Fanizzi, C., DiMeco, F., Haim, O., Peleg Hason, S., Ram, Z., Bashat, D.B., and Grossman, R. (2020). Virtual Biopsy Using MRI Radiomics for Prediction of BRAF Status in Melanoma Brain Metastasis. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-63821-y"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Gill, A.B., Rundo, L., Wan, J.C.M., Lau, D., Zawaideh, J.P., Woitek, R., Zaccagna, F., Beer, L., Gale, D., and Sala, E. (2020). Correlating Radiomic Features of Heterogeneity on CT with Circulating Tumor DNA in Metastatic Melanoma. Cancers, 12.","DOI":"10.3390\/cancers12123493"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Sun, Y., and Guo, J. (2020). Pilot Study of CT-Based Radiomics Model for Early Evaluation of Response to Immunotherapy in Patients with Metastatic Melanoma. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01524"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/9\/4561\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:53:14Z","timestamp":1760161994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/9\/4561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,27]]},"references-count":86,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["ijms22094561"],"URL":"https:\/\/doi.org\/10.3390\/ijms22094561","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,27]]}}}